2010-01-13
Probi’s dietary supplement for gut health to be rolled out in Latin America by Merck
Probi’s partner Institut Rosell has signed an agreement giving the German pharmaceutical company, Merck KGaA, an exclusive right in the pharmacy channel to sell a dietary supplement based on Probi’s bacteria, Lp299v, in 13 countries in South and Central America. The first product launches will take place in 2010 and further markets will then be added gradually when regulatory approvals are granted.